Principles of early stopping of randomized trials for efficacy: A critique of equipoise and an alternative nonexploitation ethical framework

被引:29
作者
Buchanan, D [1 ]
Miller, FG [1 ]
机构
[1] NIH, Unit Clin Res, Dept Clin Bioeth, Bethesda, MD 20892 USA
关键词
D O I
10.1353/ken.2005.0010
中图分类号
B82 [伦理学(道德学)];
学科分类号
摘要
Recent controversial decisions to terminate several large clinical trials have called attention to the need for developing a sound ethical framework to determine when trials should be stopped in light of emerging efficacy data. Currently, the fundamental rationale for stopping trials early is based on the principle that equipoise has been disturbed. We present an analysis of the ethical and practical problems with the "equipoise disturbed" position and describe an alternative ethical framework based on the principle of nonexploitation. This framework acknowledges the need for balancing the dual ethical obligations of clinical research, the protection of human subjects and the generation of new medical knowledge. Based on this framework, we put forward a proposal to make early stopping guidelines more stringent under specified conditions. The temporary withholding of apparent benefits in certain circumstances is justified by achieving a fair contract with the research participants, one that protects them from undue harm and exploitation while reducing the many uncertainties surrounding new investigational treatments that arise when trials are stopped prematurely.
引用
收藏
页码:161 / 178
页数:18
相关论文
共 35 条
[1]  
[Anonymous], 1998, The ethics biomedical research: An international perspective
[2]  
[Anonymous], 1989, EMPIRE CHSNCE PROBAB
[3]   FALSE HOPES AND BEST DATA - CONSENT TO RESEARCH AND THE THERAPEUTIC MISCONCEPTION [J].
APPELBAUM, PS ;
ROTH, LH ;
LIDZ, CW ;
BENSON, P ;
WINSLADE, W .
HASTINGS CENTER REPORT, 1987, 17 (02) :20-24
[4]  
Baum M, 2002, LANCET, V359, P2131
[5]  
Braithwaite R. B, 1959, Scientific explanation: A study of the function of theory, probability, and law in science
[7]   Letrozole after tamoxifen for breast cancer - What is the price of success? [J].
Bryant, J ;
Wolmark, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (19) :1855-1857
[8]  
BUCHANAN D, 2004, ANN M AM SOC BIOETH
[9]   The ethics of early stopping rules: Who is protecting whom? [J].
Cannistra, SA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1542-1545
[10]   A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer [J].
Coombes, RC ;
Hall, E ;
Gibson, LJ ;
Paridaens, R ;
Jassem, J ;
Delozier, T ;
Jones, SE ;
Alvarez, I ;
Bertelli, G ;
Ortmann, O ;
Coates, AS ;
Bajetta, E ;
Dodwell, D ;
Coleman, RE ;
Fallowfield, LJ ;
Mickiewicz, E ;
Andersen, J ;
Lonning, PE ;
Cocconi, G ;
Stewart, A ;
Stuart, N ;
Snowdon, CF ;
Carpentieri, M ;
Massimini, G ;
Bliss, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) :1081-1092